Are CROs an Unnecessary Expense?
In this episode, Charles Theuer discusses the potential drawbacks of Clinical Research Organizations in pharmaceutical clinical development, and what can be done to improve it.
He critiques the payment model for CROs, highlighting inefficiencies and advocating for in-house trial management, proposing alternatives, and introducing his book on optimizing drug development processes.
Tune in to learn more about in-house trial management and how to improve efficiency and reduce costs in drug development by adopting alternative models to CROs!
Click this link to the show notes, transcript, and resources: outcomesrocket.health
Outcomes Rocket